{"id":"W4415280517","doi":"10.1158/2767-9764.crc-25-0305","title":"The ATR Inhibitor Elimusertib in Combination with Cisplatin in Patients with Advanced Solid Tumors: A California Cancer Consortium Phase I Trial (NCI 10404)","year":2025,"lang":"en","type":"article","venue":"Cancer Research Communications","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"National Cancer Institute; AstraZeneca; Bristol-Myers Squibb; Eli Lilly and Company; Pharmaceuticals Bayer; Ipsen; Astellas Pharma; Eisai; Gilead Sciences; Pfizer; National Institutes of Health; U.S. Department of Health and Human Services","keywords":"Cisplatin; Solid tumor; Clinical trial; Cancer; Phases of clinical research; Ataxia-telangiectasia","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007792821,0.0001470103,0.0001851594,0.000177393,0.0003660409,0.00006044773,0.0008373153,0.00009063114,0.0000101479],"category_scores_gemma":[0.0003234599,0.0001094032,0.00003099903,0.0007711619,0.0003934152,0.00001652641,0.0004058991,0.0004673918,0.000002770523],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003322152,"about_ca_system_score_gemma":0.001114495,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005773156,"about_ca_topic_score_gemma":0.01983083,"domain_scores_codex":[0.9979988,0.0005114763,0.0003690413,0.0003331246,0.0003678743,0.0004197059],"domain_scores_gemma":[0.9976775,0.0001663305,0.0001119745,0.001384754,0.0005882142,0.00007123461],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.2821341,0.0151491,0.2201997,0.0003841668,0.0008721177,0.00001776516,0.002281244,0.003392658,0.2874394,0.00803822,0.01037964,0.1697119],"study_design_scores_gemma":[0.471415,0.01468634,0.06322917,0.003970871,0.0001304087,0.000002213776,0.003260566,0.006873728,0.2875588,0.001983708,0.1449726,0.001916524],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938768,0.001344275,0.0000866726,0.002157051,0.000061548,0.00198578,0.00009732718,0.00001475578,0.0003758499],"genre_scores_gemma":[0.9949703,0.0008927733,0.0002921936,0.00009607992,0.00002526496,0.003200325,0.0001775831,0.00002479492,0.0003206633],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1892809,"threshold_uncertainty_score":0.9980547,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02733874823644689,"score_gpt":0.3955000211396913,"score_spread":0.3681612729032444,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}